Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

A solid enough 1Q25

QBE Insurance Group
3:27pm
May 12, 2025
QBE’s 1Q25 update was broadly as expected, with key guidance parameters re-affirmed. We leave our QBE FY25F/FY26F EPS largely unchanged. Our target price rises to A$24.07 (from A$23.79) on our earnings changes and a valuation roll-forward. Whilst QBE has re-rated in line with our investment thesis, it still trades on only ~11.8x earnings, which is a significant discount to peers SUN and IAG (~17-19x). We maintain our ADD recommendation with >10% TSR upside existing.

International Spotlight

Walt Disney Company
3:27pm
May 12, 2025
The Walt Disney Co. operates as a global entertainment company. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer (DTC) services, amusement parks, cruise lines and hotels. It operates through the following business lines: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on 16 October 1923 and is headquartered in Burbank, California.

Broadly as expected at the headline level

Macquarie Group
3:27pm
May 11, 2025
MQG’s FY25 NPAT (A$3.7bn) was +1% above Factset consensus (A$3.7bn). Overall, we saw this result as largely as expected, with the positive share price reaction (+3%) likely reflecting a more stable result outcome versus MQG’s recent history of earnings disappointments. We downgrade our MQG FY26F/FY27F EPS by 2%-3%. Our PT rises to A$223 with our earnings changes offset by a valuation roll-forward. MQG is a quality franchise, and with a recent pull back in the share price occurring linked to macro and global trade factors, we see upside and move to an ADD (from Hold) recommendation.

A stable performer despite the volatile macro

REA Group
3:27pm
May 11, 2025
REA’s 3Q25 performance was largely driven by a strong yield growth (+15%) outcome in the resilient domestic residential business. REA India’s topline growth was also a key highlight, being up 28% on pcp despite the market remaining competitive. Group revenue and EBITDA (excl. associates) were up 12% in the quarter vs the pcp. We make only minor adjustments to our FY25-FY27 EPS forecasts (-0.4%), largely related to our 2H25 volume growth assumption given REA’s FY25 growth guidance. Our price target increases slightly to A$250 (from A$248) on the timing impacts of our DCF-derived valuation. Hold maintained.

Cost control

Civmec
3:27pm
May 9, 2025
3Q revenue was softer than expectations, though costs were well managed, which saw the company’s EBITDA margin rise to 12.1% from 10.5% at 1H. The company has given soft guidance for 4Q to be similar to 3Q which implies FY25 revenue of $818m and NPAT of $42.5m. The order book has risen for the first time in some time to >$760m ($633m at 1H), which ordinarily signals a return to growth. We trim our FY25 EBITDA and NPAT forecasts by 3% and 5% respectively. For FY26-27, we reduce our EBITDA forecasts by 3-4% and NPAT by 4-7%. The stock is cheap (~12x FY25 PE) and is yielding a 6% dividend (fully-franked) but we see a lack of near-term catalysts outside of the Landing Craft Heavy (LCH) naval shipbuilding contract, for which the timing is uncertain. We retain our Hold recommendation, though we see significant long-term potential in the business, particularly given the defence angle.

On wood

Avita Medical
3:27pm
May 9, 2025
AVH produced an optically difficult quarter. Strong progress year-on-year (sales +67%), but little to show on a consecutive quarterly basis (sales flat) on the key market focus metrics of sales and cash burn (which increased). Granted, it’s a seasonally weaker sales and higher expense period, but with cash balance versus burn getting tight, it needed a better print to address cash concerns. However, cost-cutting initiatives and commercial launches are expected to hit from 2Q and expected to see a material change and on its way to cashflow breakeven in 2H25 and profitability on a run-rate basis by 4Q25. Based on the new cost savings, RECELL growth (including mini), and new products, we still view guidance as achievable but also have to assume at this point a capital injection is required. Given the increased risks, the market appears to have reservations about their ability to deliver on guidance. Our valuation falls to A$3.76 (from A$4.36) and we move AVH to a Speculative Buy recommendation (from Add) given the increased balance sheet risk.

1Q25 result: Earnings to scale from here

Light & Wonder
3:27pm
May 9, 2025
Light & Wonder’s (NDAQ/ASX: LNW) 1Q25 result came in below both our forecasts and market expectations, although managed to deliver the double digit earnings growth it guided to on the last quarterly call, with Adj-EBITDA growing 11% yoy to US$311m, while margins improved 300bps following improved mix. Importantly, the company outlined the building blocks underpinning its outlook, despite the noise around the macro and Trump-era tariffs. We view the recent sell-off as a compelling entry point ahead of this month’s Investor Day in New York, particularly given the valuation support at current levels (FY26F PER ~13x). We continue to prefer LNW over peer Aristocrat (ALL) on valuation grounds. Our FY25-26F earnings estimates are largely unchanged. Retain Add rating, A$193 target price.

Sales continue to build

Polynovo
3:27pm
May 9, 2025
PNV has provided a trading update for the 9 months ended March 2025, noting sales growth of 31.1%. We are confident our FY25 forecast can be achieved and this rate of growth will continue in 4Q25. PNV has made progress on the regulatory front with a number of approvals achieved during the quarter and importantly the data for the full thickness burns trial is shortly to be locked and then submitted to the FDA to commence the approval process (expected to take six months). A search for a new CEO is underway and we view this as an important step for leadership stability. Given the positive sales momentum we have upgraded our recommendation to Speculative Buy (from Hold). Our new target price is A$1.69 (was $1.37).

Flat underlying; switch to conserving/growing capital

ANZ Banking Group
3:27pm
May 8, 2025
Strong 1H25 headline earnings growth beat consensus but was flat excluding the Suncorp Bank acquisition. We make material downgrades to forecast cash earnings (which were previously more bullish than consensus). We see approaching capital tightness in the CET1 ratio. ANZ is seeking to retain (slow and extend the existing buyback, held the DPS flat) and issue (DRP) capital. Hence, the outlook for ROE and per share metrics is poorer than previously. 12 month target price downgraded c.8% to $24.51/sh. Cash yield c.5.6%.

Mix and margin benefits = strong growth

Orica
3:27pm
May 8, 2025
ORI’s 1H25 result was strong and beat consensus EBIT and NPAT by 5.4% and 9.7% respectively. Underlying EBIT, NPAT, EPS and DPS all increased 34%/40%/33%/32% on the pcp. ORI is on track to report strong growth for the full year and has also provided positive outlook commentary for FY26. We have made minor upgrades to our forecasts which were previously above consensus estimates. With leverage to attractive industry fundamentals, market leading positions, strong earnings growth, proven management team and strong balance sheet, we think ORI’s trading multiples are undemanding and reiterate our Add rating.

News & Insights

Michael Knox, Chief Economist, reveals how the OECD and RBA’s outdated assumptions about global trade fail to account for China’s Marxist-Leninist economic strategies.

This morning, I was asked to discuss Sarah Hunter’s presentation from yesterday. Sarah, the Assistant Governor and Chief Economist at the Reserve Bank of Australia (RBA), delivered a detailed and competent discussion on the conventional view of tariffs’ impact on the international economy. She highlighted that tariffs typically increase inflation and reduce economic output, a perspective echoed by the OECD in a similar presentation overnight. Sarah’s analysis focused on the potential shocks tariffs could cause, particularly their effects on GDP and inflation.

Drawing on my experience as an Australian trade commissioner and my work in Australian embassies, I found her presentation particularly interesting. My background allowed me to bring specialist knowledge to the conversation, which I believe gave me an edge. Notably, I observed that the RBA seems to lack analysts closely tracking individual policymakers in the Trump administration, such as Scott Bessent, whose views on tariffs and competition differ from the general assumptions. The conventional view assumes a world of perfectly competitive countries adhering to international trade rules and unlikely to engage in conflict—a scenario that doesn’t align with the current global trade environment, especially between China and the United States.

China, operating as a Marxist-Leninist economy, aims to dominate global markets by building monopolies in areas like rare earths, nickel, copper, and other base metals. It maintains a managed exchange rate, despite promises to the International Monetary Fund for a freely floating currency. If China allowed its currency, the RMB, to float, it would likely appreciate significantly, increasing imports and reducing its trade surplus. This would create a more balanced international trade environment, potentially reducing the need for other countries to impose tariffs. However, major institutions like the OECD and RBA seem to misjudge the nature of this trade shock, relying on outdated assumptions about global trade dynamics.

The international community also appears to overlook specific U.S. policy intentions, such as those articulated by figures like Peter Navarro and Scott Bessent. The U.S. aims to use tariffs selectively to bolster industries like pharmaceuticals, precision manufacturing, and motor vehicles. This misunderstanding leads public institutions to perceive unspecified risks, as reflected in Sarah’s otherwise able presentation. Because the RBA and similar institutions view the world as fraught with undefined risks, they are inclined to keep interest rates low, responding to perceived threats rather than an equilibrium model.

Interestingly, data from the U.S. economy contradicts the expected negative impacts of tariffs. The Chicago Fed National Activity Indicator, a reliable gauge of economic growth since the 2008 financial crisis, shows U.S. growth above the long-term trend for the first four months of this year. This suggests resilience despite tariff-related shocks. Ideally, growth will slow later this year, prompting the Federal Reserve to cut rates, facilitating a soft landing and a decline in the U.S. dollar to boost global commodity prices. However, this nuanced outlook wasn’t evident in yesterday’s presentation.

Moreover, the anticipated rise in U.S. inflation due to tariffs isn’t materialising. Scott Bessent recently noted that U.S. CPI inflation is lower than expected, with core inflation shown as the (16% trimmed mean) at 3% for the past two months . Core inflation  excluding  food and energy CPI  is only at 2.8%. This suggests that Chinese suppliers are absorbing tariff costs to maintain market share, rather than passing them on as higher prices. Recent Chinese data supports this, showing a slight decline in manufacturing confidence and coal consumption, indicating reduced factory output and electricity use. This points to a modest slowdown in China’s economy. So far the expected negative effects on U.S. prices and output are not occurring.

In summary, the fears expressed by institutions like the RBA and OECD about the Trump administration’s trade policies appear overstated. The U.S. economy is not experiencing the predicted declines in output or increases in inflation. While these effects may emerge later, the current data suggests that the risks are not as severe as anticipated, highlighting a disconnect between theoretical models and real-world outcomes.

Read more
Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more